Abstract
The aim of this case study is to review the literature and report the first published case of olanzapine-induced acute pancreatitis in New Zealand. A case report of acute pancreatitis with new onset diabetes mellitus secondary to olanzapine in a 42-year-old male, in the absence of medical risk factors is reported. Eleven previous case reports of olanzapine induced acute-pancreatitis were identified in the literature. A 42-year-old male was diagnosed with acute pancreatitis and new diabetes mellitus induced by olanzapine. Although rare, pancreatitis is associated with use of some atypical antipsychotic medications. It is important for prescribers to be aware of this potentially fatal side effect. In addition to this, we are highlighting the well documented evidence of metabolic disruption associated with olanzapine.
Highlights
A case report of acute pancreatitis with new onset diabetes mellitus secondary to olanzapine in a 42-year-old male, in the absence of medical risk factors is reported
A 42-year-old male was diagnosed with acute pancreatitis and new diabetes mellitus induced by olanzapine
Adverse side-effects associated with the use atypical antipsychotic medications (AAPs) are widely recognised; this has led to specific recommendations for regular side effect monitoring throughout a course of treatment [1,2]
Summary
Adverse side-effects associated with the use atypical antipsychotic medications (AAPs) are widely recognised; this has led to specific recommendations for regular side effect monitoring throughout a course of treatment [1,2]. Adverse outcomes include over sedation, metabolic derangement, extrapyramidal side effects, myocarditis, prolonged QTc interval, toxic megacolon and agranulocytosis [1,2,3]. The aim of this case report is to review the literature and describe the first published episode of olanzapineinduced pancreatitis in New Zealand. Its use was restricted by special authority criteria and required application from a psychiatrist for a patient who had been trialled unsuccessfully on risperidone or required treatment with olanzapine short acting intra-muscular injection [4]. In June 2011, significantly cheaper generic versions of olanzapine were introduced and the special authority criteria for olanzapine withdrawn [5]. We aim to highlight lesser known and potentially fatal side effects through our case report
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
